Payment overview · 2025
General Payments
$39,823.98
170 reported records · 15 companies
Healthcare provider profile · identity verified
Douglas Conaway, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · MYRTLE BEACH, SC · NPI 1316944499
Verified facts
What the public records show
CMS Open Payments records show Douglas Conaway, M.D. received $39,823.98 in general payments during 2025 across 170 reported records.
Janssen Biotech, Inc. accounted for 55.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Orencia, Tavneos.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HUMIRA as an associated drug or biological on 1828 records involving 689 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Humira by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TAVNEOS as an associated drug or biological on 21404 records involving 7606 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Tavneos by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORENCIA as an associated drug or biological on 10404 records involving 2463 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Orencia by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SIMPONI as an associated drug or biological on 23185 records involving 7011 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Simponi by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $22,166.04 | 55.7% | 45 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $9,913.09 | 24.9% | 50 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $5,833.80 | 14.7% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $1,101.46 | 2.8% | 36 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $392.02 | 1.0% | 15 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $91.57 | 0.2% | 4 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $66.32 | 0.2% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $44.28 | 0.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $40.18 | 0.1% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $36.48 | 0.1% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $34.52 | 0.1% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $34.08 | 0.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.48 | 0.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.35 | 0.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.31 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $29,338.00 | 10 |
| Travel and Lodging | $4,130.71 | 17 |
| Food and Beverage | $4,020.28 | 141 |
| Consulting Fee | $2,280.00 | 1 |
| Education | $54.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $22,166.04 | 45 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $19,520.47 | 23 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $9,242.23 | 23 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $5,833.80 | 7 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $573.17 | 23 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $392.02 | 15 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $252.86 | 7 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $103.88 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $94.73 | 7 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $91.57 | 4 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $68.30 | 5 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $66.36 | 5 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $66.32 | 2 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $66.32 | 2 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $66.32 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $44.28 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $40.18 | 2 | 2025 |
Source payment records
|
|||||
| ORENCIA Normalized: orencia |
Biological | E.R. Squibb & Sons, L.L.C. | $36.48 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $34.52 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $34.08 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $29.48 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| ENBREL Normalized: enbrel |
Biological | Amgen Inc. | $7.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ORENCIA orencia |
2025 | Orencia | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TAVNEOS tavneos |
2025 | Tavneos | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | HUMIRA open payments reported associated product |
CMS Open Payments — General Payments 1828 supporting records · 689 recipient NPIs · example record 1201353784 |
Humira · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | TAVNEOS open payments reported associated product |
CMS Open Payments — General Payments 21404 supporting records · 7606 recipient NPIs · example record 1226871817 |
Tavneos · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ORENCIA open payments reported associated product |
CMS Open Payments — General Payments 10404 supporting records · 2463 recipient NPIs · example record 1184378623 |
Orencia · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | SIMPONI open payments reported associated product |
CMS Open Payments — General Payments 23185 supporting records · 7011 recipient NPIs · example record 1174257377 |
Simponi · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 414 | 102 |
| Duloxetine Hcl | Duloxetine Hcl | 279 | 68 |
| Gabapentin | Gabapentin | 237 | 74 |
| Methotrexate | Methotrexate Sodium | 227 | 66 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 189 | 33 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 179 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 162 | 27 |
| Tramadol Hcl | Tramadol Hcl | 160 | 39 |
| Celecoxib | Celecoxib | 155 | 47 |
| Prednisone | Prednisone | 135 | 43 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 128 | 38 |
| Trazodone Hcl | Trazodone Hcl | 120 | 35 |
| Alprazolam | Alprazolam | 106 | 19 |
| Pregabalin | Pregabalin | 104 | 27 |
| Leflunomide | Leflunomide | 94 | 21 |
| Sulfasalazine | Sulfasalazine | 79 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 64 | 13 |
| Leucovorin Calcium | Leucovorin Calcium | 64 | 16 |
| Omeprazole | Omeprazole | 63 | 19 |
| Bupropion Xl | Bupropion Hcl | 62 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 47 | 15 |
| Sertraline Hcl | Sertraline Hcl | 44 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 23 |
| Folic Acid | Folic Acid | 36 | 12 |
| Allopurinol | Allopurinol | 31 | suppressed |
| Methotrexate Sodium | Methotrexate Sodium/Pf | 30 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 30 | suppressed |
| Colchicine | Colchicine | 29 | suppressed |
| Ibuprofen | Ibuprofen | 29 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 28 | suppressed |
| Orencia | Abatacept | 28 | suppressed |
| Azathioprine | Azathioprine | 27 | suppressed |
| Humira(Cf) Pen | Adalimumab | 27 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 26 | suppressed |
| Lidocaine | Lidocaine | 22 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 21 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Potassium Chloride | Potassium Chloride | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 15 | suppressed |
| Azithromycin | Azithromycin | 15 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 14 | suppressed |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 14 | suppressed |
| Humira | Adalimumab | 13 | suppressed |
| Kevzara | Sarilumab | 13 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 13 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Losartan Potassium | Losartan Potassium | 12 | suppressed |
| Rasuvo | Methotrexate/Pf | 12 | suppressed |
| Simponi | Golimumab | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Enbrel Sureclick | Etanercept | 11 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Tavneos | Avacopan | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $39,823.98 · 170 records | Janssen Biotech, Inc. | Bimzelx, COSENTYX, ENBREL, EVENITY, FREESTYLE LIBRE 3, KRYSTEXXA, Kerendia, ORENCIA, OTEZLA, QULIPTA, QUTENZA, REPATHA, REZDIFFRA, RINVOQ, SIMPONI ARIA, SKYRIZI, TAVNEOS, TREMFYA, Tymlos, UBRELVY, UPLIZNA, VRAYLAR, Wegovy, XELJANZ, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Orencia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error